← Back to Search

Monoclonal Antibodies

AMG 133 for Obesity

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up part a: up to 150 days; part b and c: up to 207 days
Awards & highlights

Study Summary

This trial will test if a new drug is safe and tolerated when given to obese people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~part a: up to 150 days; part b and c: up to 207 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and part a: up to 150 days; part b and c: up to 207 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part A: Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Measurements
Part A: Number of Participants with Clinically Significant Changes in Vital Signs
Part A: Number of Participants with Clinically Significant Laboratory Values
+9 more
Secondary outcome measures
Part A, B and C: Maximum Plasma Concentration (Cmax)
Part A, B, and C: Area Under the Plasma Concentration-time Curve (AUC)
Part A, B, and C: Number of Participants with Anti-AMG 133 Antibody Formation
+1 more

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Part C: AMG 133Experimental Treatment1 Intervention
Up to 2 open-label, multiple ascending dose cohorts (cohorts 12 to 13) treated with doses previously studied in Part A and Part B.
Group II: Part B: AMG 133Experimental Treatment1 Intervention
Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
Group III: Part A: AMG 133Experimental Treatment1 Intervention
Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
Group IV: Part A: PlaceboPlacebo Group1 Intervention
Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
Group V: Part B: PlaceboPlacebo Group1 Intervention
Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMG 133
2020
Completed Phase 1
~150

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,371 Previous Clinical Trials
1,377,996 Total Patients Enrolled
8 Trials studying Obesity
957 Patients Enrolled for Obesity
MDStudy DirectorAmgen
914 Previous Clinical Trials
924,469 Total Patients Enrolled
5 Trials studying Obesity
794 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Tennessee
Other
Florida
California
How old are they?
18 - 65
What site did they apply to?
Orange County Research Center
Clinical Pharmacology of Miami, LLC
Anaheim Clinical Trials
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
2
3+

Why did patients apply to this trial?

As you get older, it gets harder to lose weight. I would just like to try something that could help.
PatientReceived no prior treatments
I would like to be apart of the Amgen AMC133 phase 2 trial ( people with type 2 diabetes, overweight.) not sure how to apply. I’m a registered nurse with 30years nephrology.
PatientReceived no prior treatments
I have had weight loss surgery (Aug 2019) and tried Ozempic and Mounjaro. I had success with those drugs, but after a change in insurance the cost to get them is prohibitive.
PatientReceived 1 prior treatment
I have tried multiple diets to the T and have not been successful. My last attempt had me finally losing weight but it took 8 months to lose 6 pounds. I am frustrated, but would like to find out other options.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
2020. "Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04478708.
~24 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top